Cite
HARVARD Citation
Nasrallah, M. et al. (2015). Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis research & therapy. 17 (1), pp. 1-11. [Online].